Lupin Delivers Strong Q4 with Robust Profit Growth and Healthy Margins

Lupin delivered a strong Q4 performance with its consolidated net profit rising to ₹7.73 billion, more than double the ₹3.59 billion posted in the same quarter last year, though sequentially lower than ₹8.55 billion in Q3. This year-on-year growth is backed by a robust 14% increase in revenue to ₹56.67 billion, indicating sustained momentum in sales, particularly from the U.S. generics and domestic formulations segments. The EBITDA also saw a significant jump to ₹13.21 billion from ₹9.97 billion, with margins improving to 23.31% from 20.09%, reflecting operational efficiency and better product mix. The continued margin expansion and healthy profitability point to improved cost control and possibly higher contribution from complex generics or niche therapies. While the slight QoQ dip in net profit could be attributed to one-offs or seasonality, the board's decision to recommend a ₹12 dividend per share signals management’s confidence in the company’s cash flows and overall financial health. Overall, Lupin's Q4 results indicate strong execution and improved fundamentals, making it a stock worth tracking in the pharma sector.